ABSTRACT
V enous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), affects approximately 1 in 1,000 people in the United States annually. 1, 2 Treatment consists of anticoagulation therapy, and evidence supports treating patients with low-risk VTEs as outpatients. [3] [4] [5] Novel oral anticoagulants such as rivaroxaban, an oral factor Xa inhibitor, are FDA-approved for the treatment of VTE and serve as an alternative therapeutic option to a parenteral anticoagulant and warfarin, as it does not require bridging therapy. As demonstrated in the EINSTEIN clinical trial, benefits to using rivaroxaban for outpatient VTE therapy instead of warfarin include less frequent monitoring, less major bleeding, fewer drug interactions, and simpler dosing regimens. 6 
Development of Outpatient VTE Clinic
The outpatient VTE clinic, also known as the clot clinic, was originally developed by emergency department (ED) physicians in March 2013 as an unfunded ED fellowship research project. Protocols were established for the outpatient treatment of VTE that included initial clinic visits between 2 and 5 weeks to establish care and again 3 to 6 months after diagnosis to determine duration of therapy. In anticipation of the fellows' graduation, the physicians engaged the pharmacy department for assistance with transitioning the clinic's management to clinical pharmacists. During a 6-month overlap period, internal medicine and critical care-trained clinical pharmacists shadowed, trained, and created a hospital leadership-approved collaborative practice agreement (CPA) outlining specific protocols and medication management procedures. Upon completion of the fellowship, pharmacy assumed the responsibilities of the clot clinic as an opportunity to expand outpatient clinical pharmacy services. After clinic implementation, pharmacists performed a study evaluating the difference in outcomes between the outpatient treatment of VTE with rivaroxaban in the pharmacist-managed clinic versus management by a primary care provider (PCP).
METHODS

Study Setting
The Eskenazi clot clinic is located within an academic, safety-net, Level I trauma center in a metropolitan city. The clinic takes place once monthly for 4 hours and provides services for up to 12 outpatients with low-risk VTE treated with rivaroxaban. The two clinical pharmacists that manage the clot clinic and facilitate patient visits dedicate this time in addition to their normal, full-time jobs providing clinical pharmacy support to internal medicine and critical care teams. This equates to a combined total of 0.05 FTEs monthly.
Study Design
This prospective, observational cohort study evaluated the difference in outcomes between the outpatient treatment of VTE with rivaroxaban in a pharmacistmanaged clinic versus management by a PCP. Outcomes were evaluated for a convenience sample of patients seen between April 2015 and September 2015. The protocol was approved by the Indiana University Institutional Review Board before initiation of the study.
Patients in the pharmacist-managed group were diagnosed by a physician with a low-risk VTE based on the absence of a modified version of the Hestia criteria in the ED. 7 For example, patients eligible for referral were required to have normal renal function (creatinine clearance > 30 mL/min), a systolic blood pressure above 100 mm Hg, and a pulse oximetry reading above 94%; were not already anticoagulated; did not warrant admission for other medical or social conditions; did not require more than two doses of intravenous narcotics and did not exhibit coagulopathy based on international normalized ratio (INR) for the prothrombin time (PT) and had a normal platelet count. After patients were diagnosed and screened for eligibilty criteria, they were discharged from the ED with a prescription for rivaroxaban and a clot clinic appointment scheduled within 1 month from presentation. As a safety-net health system, all referred patients are evaluated in clot clinic, regardless of payor source or insurance status.
Comparator group patients were selected using the hospital system's outpatient pharmacy dispense records. From the list of rivaroxaban prescriptions filled, patients were evaluated using the hospital's electronic medical record and were included for potential matching if rivaroxaban was being used to treat a VTE. Once identified for potential matching, the control group patient was matched with a pharmacist-managed patient if they met all the following criteria: month and year of rivaroxaban initiation, age (same decade of life), and sex.
Study Protocol
The clot clinic pharmacist is able to order laboratory tests and manage medications in accordance with the CPA between the clot clinic physicians and pharmacist. Laboratory tests including anti-Xa levels, basic metabolic panels, complete blood counts, D-dimers, and PT/INRs can be ordered based on the patient's history, presentation, or potential drug-drug interactions. Aspirin is considered an independent privilege, meaning it can be started, renewed, adjusted, or discontinued by the pharmacist. The pharmacist can renew, adjust, or discontinue rivaroxaban, warfarin, and enoxaparin prescriptions if originally prescribed by a physician. Any ED physician can write the original prescriptions for patients treated in the pharmacistmanaged clinic. Prothrombin complex concentrate and vitamin K can only be prescribed after provider consultation (but have not been used in any case).
Patient information collected at the pharmacist-managed clinic visit is summarized in Table 1 . Prior to seeing the patient, the pharmacist reviews the patient's electronic medical record to analyze VTE diagnosis, laboratory data, and medication list. During each visit, the pharmacist identifies VTE symptoms, performs a focused physical examination (e.g., skin assessment, calf measurements, and pain evaluation), and evaluates for postthrombotic syndrome (a syndrome resulting from thrombotic venous scarring and valve destruction leading to long-term pain and changes in blood flow). 8, 9 Assessment of adherence is performed using the four-item Modified Morisky Adherence Scale, a validated questionnaire tool for measuring medication adherence. 10 Patients are counseled on laboratory results, medication use, adherence, side effects, drug interactions, lifestyle modifications, smoking cessation, and other issues as they arise. The pharmacist determines the duration of therapy, in alignment with the CHEST guidelines, primarily based on patient biological sex, location, and nature of clot (i.e., DVT or PE, provoked or unprovoked) and if the patient has prior history of VTE. D-dimer concentrations can be used to help determine appropriate therapy duration in uncertain cases. 11, 12 A unique contribution to clinic services provided by the pharmacists includes assistance with navigating insurance-related issues including prior authorizations, patient assistance programs, and other sources of sustainable funding to facilitate medication access and ensure completion of therapy. A physician is immediately available, either on site, or by telephone for consultation if needed for more complex medical questions.
Outcomes
The primary outcome was the composite occurrence of anticoagulation treatment-related complications defined as an episode of major bleeding, recurrent thromboembolic event, or fatal event due to either bleeding or thromboembolism within 6 months of the original VTE diagnosis. The study defined major bleeding using the International Society for Thrombosis and Hemostasis definition of greater than or equal to a 2 g/dL reduction in hemoglobin or greater than or equal to 2 units of blood transfusion, bleeding in a critical area, or bleeding contributing to death. 13 Secondary endpoints included individual components of the primary outcome, number of hospitalizations after VTE diagnosis, adverse events, and Morisky medication adherence score.
Data Analysis
Statistical tests were performed using statistical software (Minitab 16, Minitab Inc.). Normally distributed data were reported with mean (AE standard deviation [SD]), whereas nonnormally distributed data were reported with median (interquartile range [IQR] ). Normality was tested using the Anderson-Darling normality test. The Student's t-test was used to detect differences between normally distributed continuous data. For continuous data that were not normally distributed, a Mann-Whitney U-test was used to examine potential differences. The Fisher's exact or chi-square tests were used to detect differences in nominal data. The significance level (alpha) was predetermined to be • Duration of rivaroxaban therapy DVT = deep vein thrombosis; PCP = primary care provider; PE = pulmonary embolism; VTE = venous thromboembolism. less than 0.05. A sample size calculation was not conducted as this was a convenience sample limited to the number of patients seen and treated in the described clinic with a corresponding number of control patients.
RESULTS
Seventeen patients were managed solely by pharmacists during the 6-month study period. The mean (AESD) patient age was 50 (AE12) years, and six patients were male (35%). Seventeen patients served as matching cohorts in the control group with a mean (AESD) patient age of 54 (AE12) years, six of whom were male (35%). Patients were well-matched in terms of age, sex, weight, smoking status, and occurrence of either DVT and/or PE. Complete demographic information is summarized in Table 2 .
Primary Outcome
There was one occurrence (6%) of the composite primary endpoint in each study arm, each of which were due to recurrent thromboembolic events (p = 1.000). These events were within the first 6 months of original VTE diagnosis and both were recurrent DVTs.
Secondary Outcomes
All secondary outcomes are summarized in Table 3 . There was one instance (6%) of VTE-related hospitalization in each study arm (p = 1.000). All other hospitalizations were not related to the patients' VTE diagnosis or treatment. Adverse events described by patients included pain, headache, and minor bleeding including menorrhagia. Overall, there were seven (41%) reported adverse events in the pharmacist care group and four (24%) in the control group (p = 0.465).
Pharmacists began using the Modified Morisky Adherence Scale to formally evaluate medication adherence 3 months after starting in the clot clinic since it had not been studied in this patient population to our knowledge. While this could influence the secondary endpoint of medication adherence, it was determined to be a necessary part of our study protocol because a lack of adherence could negatively affect patient care, directly impacting the primary outcome. All patients assessed (n = 8) had a score of 0 or 1, signifying high or medium adherence. Although a few PCP notes commented on a patient's medication adherence informally, no patients in the control group had a documented assessment of medication adherence using a formal tool. The lack of formal Data are reported as mean (AESD), n (%), or median (IQR). CrCl = creatinine clearance; DVT = deep vein thrombosis; IQR = interquartile range; PCP = primary care provider; PE = pulmonary embolism. *Calculated using actual body weight per prescribing information recommendations. †Calculated using ideal body weight per Cockcroft-Gault creatinine clearance equation. assessment in the control group could represent a confounder to the results.
DISCUSSION
Pharmacists have demonstrated the importance of their role in the outpatient health care setting based on studies showing improved patient outcomes, medication adherence, and compliance to evidence-based guidelines. Examples include increased percentage of patients on optimally dosed heart failure medications, increased medication adherence leading to decreased heart failure-related ED visits, increased percentage of patients with hypertension achieving goal blood pressures, and decreases in hemoglobin A1c in patients with diabetes. [14] [15] [16] [17] Previously published studies on pharmacist-managed warfarin clinics describe the pharmacist's ability to achieve goal INRs more frequently than PCPs, improve patient satisfaction scores, and decrease costs by optimizing the number of INRs checked. [18] [19] [20] The pharmacist-managed clot clinic is a unique expansion of outpatient clinical pharmacy services. In the clot clinic, not only are pharmacists managing and monitoring anticoagulants, they are also independently managing VTE treatment duration, assessing adherence, and ensuring sustainability of drug therapy.
This study compares patient outcomes in the pharmacist-managed clinic versus those managed by a PCP. Because the pharmacist-managed clinic is the only formalized outpatient service treating patients with lowrisk VTE, there were challenges in selecting a control group. A few control group patients were hospitalized as a result of their original VTE diagnosis, potentially selecting for a higher-risk control group. It was not possible to retrospectively evaluate the severity of VTE using the Hestia criteria in the control group due to documentation limitations in the electronic medical record. Restrictive, predetermined inclusion criteria were used for control group patients to ensure they were matched as closely as possible with intervention group patients. The goal of a matched control group was to minimize confounders allowing for a more accurate comparison of pharmacist-managed versus PCP-managed care.
Although a power calculation was not performed due to the convenience sample of our study, the primary outcome indicated pharmacist-managed care was potentially as safe as care by a PCP and helped justify long-term pharmacist management in the clinic. The similar secondary outcome results further support the safety of a pharmacist-managed clinic. A post hoc power calculation demonstrated that to achieve 80% power to detect at least a 10% difference in the primary outcome between study groups, 153 patients would need to be enrolled in each arm of the study. Based on current enrollment rates, this would take at least 6 years with our single center.
There were a higher number of documented adverse events noted in the pharmacist-managed group, which could be due to recall bias. However, given the small number of events overall, this may have been due to differences in the questions asked to the patient and documentation practices. By using a standardized question list and note template, pharmacists ensured that they would not omit asking about or reporting adverse events. Menorrhagia was the most common adverse event reported by female patients in the clot clinic. To address this concern, the pharmacist-managed protocol specifies holding no more than one dose of rivaroxaban if the patient has heavy uterine bleeding (i.e., menstrual bleeding considered heavy by the patient and lasting 5 or more days, or 2 consecutive days requiring 10 or more pads).
There are several strengths and limitations of our study. Strengths include the unique expansion of clinical pharmacy services in a safety-net health care system, use of a matched control group, prospective data collection related to VTE outcomes, and the use of a verified tool to evaluate medication adherence in the intervention group. An additional strength evident in the study due to clinical pharmacist involvement includes detailed medication profile reviews which encompass formal drug-drug interaction screening, side effect evaluation, and renal dose adjustments. Pharmacists also spend a significant portion of each clinic appointment counseling and educating patients on medication use, disease state, lifestyle modifications, and smoking cessation if applicable. Limitations include slow patient recruitment at the start of the study, limited ability to determine the true rate of adverse events due to variation in documentation practices, and the use of only one anticoagulant in the clinic. All of these may have contributed to our small sample size and the inability to achieve power, as highlighted above. The retrospective nature of the data collection in the control group has the potential to bias results due to potential lack of documentation by the PCP. While most of these limitations are unavoidable, clinic volumes have since increased and pharmacists have added apixaban to their CPA to broaden the list of anticoagulants that can be prescribed. The small size of the convenience sample included in our study made statistical analysis demonstrating significance difficult, which could have resulted in a type II error. Also, while we attempted to control for confounders by matching patients to historical controls, using a propensity score may allow for a more rigorous comparison in a future study utilizing a larger sample size. However, our results should be seen as hypothesis generating, warranting further studies with larger patient populations or across multiple sites.
Financial Justification of Services
Outpatient treatment of VTE using rivaroxaban can result in significant cost savings. In a previously published evaluation of low-risk VTE outpatient treatment costs for 97 patients within the same study institution, the median cost for the first 6 months of care for patients treated with enoxaparin and warfarin was $9,016 (IQR = $3,535 to $10,622) versus $5,932 (IQR = $4,745 to $8,594) with rivaroxaban (n = 45). This 6-month median difference per patient of $3,084 approximates $515 of cost savings per month of VTE treatment using rivaroxaban instead of enoxaparin and warfarin. 21 We hypothesize that the cost savings associated with outpatient treatment of VTE using rivaroxaban, compared to warfarin, is due to the decreased need for laboratory monitoring and subsequent provider visits.
During the first 10 months of pharmacist-management in clinic, 27 unique outpatients were treated though not all were included in the data analysis due to not being 6 months from diagnosis. Among these patients, there were 182 treatment months, which yields an estimated $93,730 of cost savings for VTE treatment using rivaroxaban instead of enoxaparin and warfarin (based on the cost savings described). 21 It is important to note that this cost savings originates from the ED physician's decision to treat the patient with a low-risk VTE as an outpatient. With this decision, cost savings allowed for resources to be allocated toward the expansion of clinical pharmacy services, into the clot clinic. Additional savings could be realized when comparing the salaries and benefits required for clinical pharmacist hours versus PCP hours spent in clinic. As the time spent per patient visit was not documented in either group, and due to the retrospective nature of this study, this was not included in the estimate above.
CONCLUSIONS
The pharmacist-managed venous thromboembolism clinic using non-warfarin oral anticoagulants is a unique expansion of pharmacy services not yet described in the literature. Pharmacists are now independently managing all clot clinic patient care activities under a collaborative practice agreement and have expanded responsibilities to include apixaban. Pharmacists contribute distinct insight to clot clinic patient care by performing detailed reviews of medication lists, screening for drug interactions, counseling on adherence and disease state education, and ensuring sustainable access to their medication for the complete duration of therapy. Future directions include evaluating outcomes with a larger sample size, matching patients to controls using a propensity score, and conducting a survey to assess patient and provider satisfaction with the pharmacistmanaged clot clinic. This study supports the expansion of pharmacy services in the clot clinic to promote safety, efficacy, and cost savings.
